Aclaris Therapeutics (NASDAQ:ACRS) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a research report released on Saturday morning.

Other research analysts have also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, January 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. Finally, Craig Hallum began coverage on Aclaris Therapeutics in a research report on Friday, January 30th. They issued a “buy” rating and a $10.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Trading Down 1.9%

ACRS opened at $3.06 on Friday. The company has a fifty day simple moving average of $3.25 and a 200 day simple moving average of $2.65. The firm has a market cap of $369.04 million, a price-to-earnings ratio of -5.77 and a beta of 0.88. Aclaris Therapeutics has a twelve month low of $1.05 and a twelve month high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The firm had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.07 million. Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%. On average, analysts forecast that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC lifted its stake in Aclaris Therapeutics by 111.0% in the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares during the last quarter. Geode Capital Management LLC lifted its position in Aclaris Therapeutics by 108.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after purchasing an additional 1,282,042 shares during the last quarter. Acadian Asset Management LLC boosted its stake in Aclaris Therapeutics by 10.9% during the 2nd quarter. Acadian Asset Management LLC now owns 2,433,850 shares of the biotechnology company’s stock valued at $3,453,000 after purchasing an additional 238,659 shares during the period. Kotler Kevin acquired a new position in Aclaris Therapeutics during the 4th quarter valued at about $5,135,000. Finally, Palo Alto Investors LP grew its position in Aclaris Therapeutics by 12.7% in the 3rd quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock worth $2,977,000 after purchasing an additional 176,812 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.